[{"id":"3ba5c955-8ec9-4668-a6f6-e10f2a3b745e","acronym":"","url":"https://clinicaltrials.gov/study/NCT07004075","created_at":"2025-06-07T14:43:33.080Z","updated_at":"2025-06-07T14:43:33.080Z","phase":"Phase 3","brief_title":"FCN-159 Monotherapy Versus Chemotherapy by Investigator's Choice in Pediatric Low-grade Glioma Patients With BRAF Alteration","source_id_and_acronym":"NCT07004075","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • temozolomide • Ivesa (firmonertinib) • Fu Mai Ning (luvometinib) • vindesine"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 102","initiation":"Initiation: 06/30/2025","start_date":" 06/30/2025","primary_txt":" Primary completion: 04/30/2027","primary_completion_date":" 04/30/2027","study_txt":" Completion: 04/30/2029","study_completion_date":" 04/30/2029","last_update_posted":"2025-06-04"},{"id":"858789a0-ffc7-4b5d-93c6-6eb6690616c1","acronym":"","url":"https://clinicaltrials.gov/study/NCT06553365","created_at":"2025-02-27T08:06:57.659Z","updated_at":"2025-02-27T08:06:57.659Z","phase":"Phase 2","brief_title":"Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors","source_id_and_acronym":"NCT06553365","lead_sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","biomarkers":" NF2","pipe":"","alterations":" ","tags":["NF2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 08/15/2024","start_date":" 08/15/2024","primary_txt":" Primary completion: 07/31/2026","primary_completion_date":" 07/31/2026","study_txt":" Completion: 07/31/2026","study_completion_date":" 07/31/2026","last_update_posted":"2024-08-14"},{"id":"567a8aef-1c29-45f6-aa4c-73624212b548","acronym":"","url":"https://clinicaltrials.gov/study/NCT03932253","created_at":"2021-01-18T19:22:09.234Z","updated_at":"2024-07-02T16:35:12.608Z","phase":"Phase 1","brief_title":"MEK Inhibitor FCN-159 To Treat Advanced Melanoma With NRAS-aberrant (Ia) and NRAS-mutant (Ib)or NF1-mutant(1b)","source_id_and_acronym":"NCT03932253","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" NRAS • NF1","pipe":" | ","alterations":" NRAS mutation","tags":["NRAS • NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRAS mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Suspended","enrollment":" Enrollment 79","initiation":"Initiation: 03/21/2019","start_date":" 03/21/2019","primary_txt":" Primary completion: 04/30/2023","primary_completion_date":" 04/30/2023","study_txt":" Completion: 04/30/2024","study_completion_date":" 04/30/2024","last_update_posted":"2024-03-27"},{"id":"5464bbe9-0507-491a-a174-c662a80c8226","acronym":"","url":"https://clinicaltrials.gov/study/NCT05913037","created_at":"2023-06-22T19:11:30.805Z","updated_at":"2024-07-02T16:35:14.460Z","phase":"Phase 3","brief_title":"FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas","source_id_and_acronym":"NCT05913037","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" NF1","pipe":"","alterations":" ","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 162","initiation":"Initiation: 06/20/2023","start_date":" 06/20/2023","primary_txt":" Primary completion: 06/30/2025","primary_completion_date":" 06/30/2025","study_txt":" Completion: 06/30/2026","study_completion_date":" 06/30/2026","last_update_posted":"2024-03-15"},{"id":"71baff50-e314-4a96-b786-467f5f3dd5d1","acronym":"","url":"https://clinicaltrials.gov/study/NCT04954001","created_at":"2021-07-08T14:52:37.523Z","updated_at":"2024-07-02T16:35:33.023Z","phase":"Phase 2","brief_title":"Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1","source_id_and_acronym":"NCT04954001","lead_sponsor":"Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.","biomarkers":" NF1","pipe":" | ","alterations":" NF1 mutation","tags":["NF1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NF1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Fu Mai Ning (luvometinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 160","initiation":"Initiation: 03/26/2021","start_date":" 03/26/2021","primary_txt":" Primary completion: 02/28/2025","primary_completion_date":" 02/28/2025","study_txt":" Completion: 03/30/2025","study_completion_date":" 03/30/2025","last_update_posted":"2023-10-17"}]